SCHEMBL1481334

SCHEMBL1481334

[CH]=Cc1ccccc1OC

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ NFE2L2 Q16236 5/20 0.55
▸ TRPA1 O75762 1/20 0.55
▸ CA1 P00915 3/20 0.55
▸ CA2 P00918 3/20 0.55
▸ CA7 P43166 2/20 0.55
▸ CA9 Q16790 2/20 0.55
▸ CA12 O43570 1/20 0.55
▸ CA4 P22748 1/20 0.55
▸ CA14 Q9ULX7 1/20 0.55
▸ TFEB P19484 1/20 0.52
▸ CYP1A2 P05177 4/20 0.50
▸ CYP1A1 P04798 3/20 0.50
▸ CYP1B1 Q16678 3/20 0.50
▸ KDM4E B2RXH2 2/20 0.50
▸ CYP19A1 P11511 1/20 0.48
▸ ALDH1A1 P00352 3/20 0.48
▸ MAPK1 P28482 1/20 0.48
▸ HTT P42858 1/20 0.48
▸ L3MBTL1 Q9Y468 1/20 0.48
▸ GRIN2D O15399 2/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7770731 0.81 NFE2L2 (0.55) NFE2L2TRPA1CA1CA2CA7
SCHEMBL4642599 0.80 NFE2L2 (0.58) NFE2L2CYP1A2CYP1A1CYP1B1KDM4E
SCHEMBL4019329 0.80 NFE2L2 (0.79) NFE2L2TRPA1CA1CA2CA7
SCHEMBL7915752 0.80 NFE2L2 (0.79) NFE2L2TRPA1CA1CA2CA7
SCHEMBL240090 0.80 CA1 (0.60) NFE2L2TRPA1CA1CA2CA7
SCHEMBL1603719 0.80 NFE2L2 (0.79) NFE2L2TRPA1CA1CA2CA7
SCHEMBL7051005 0.78 NFE2L2 (0.61) NFE2L2TRPA1CA1CA2CA7
SCHEMBL98304 0.78 NFE2L2 (0.57) NFE2L2TRPA1CA1CA2CA7
SCHEMBL9900653 0.77 NFE2L2 (0.62) NFE2L2TRPA1CA1CA2CA7
SCHEMBL1305544 0.76 NFE2L2 (0.55) NFE2L2TRPA1CA1CA2CA7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 234 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-113004194-B Circular polarization luminescent organic micro-nano crystal material and preparation method and application thereof 中国科学院化学研究所 2022-12-09 — — CN claimed
CN-108794407-B Cationic antioxidant corrosion inhibitor and preparation method thereof 西南石油大学 2022-10-28 — — CN claimed
CN-114959712-A Vapor phase corrosion inhibitor and preparation method thereof 中国石油化工股份有限公司 2022-08-30 — — CN claimed
CN-113214238-A Preparation and application of indole oxadiazole derivative with acylated piperazine structure 济南大学 2021-08-06 — — CN claimed
US-8183239-B2 Substituted piperazines and piperidines as modulators of the neuropeptide Y2 receptor JANSSEN PHARMACEUTICA NV (BE) 2012-05-22 — — US claimed
EP-1948629-A1 SUBSTITUTED PIPERAZINES AND PIPERIDINES AS MODULATORS OF THE NEUROPEPTIDE Y2 RECEPTOR JANSSEN PHARMACEUTICA N.V. (BE) 2008-07-30 — — EP claimed
EP-1218337-B1 SYNTHESIS OF 3,5,7|-1H-IMIDAZO 1,5-A|IMIDAZOL-2(3H)-ONE COMPOUNDS TORREY PINES INST (US) 2007-10-31 — — EP claimed
WO-2007053436-A1 SUBSTITUTED PIPERAZINES AND PIPERIDINES AS MODULATORS OF THE NEUROPEPTIDE Y2 RECEPTOR JANSSEN PHARMACEUTICA N.V. (BE) 2007-05-10 — — WO claimed
US-20070100141-A1 SUBSTITUTED PIPERAZINES AND PIPERIDINES AS MODULATORS OF THE NEUROPEPTIDE Y2 RECEPTOR JANSSEN PHARMACEUTICA N.V. (BE) 2007-05-03 — — US claimed
JP-2006518738-A — — 2006-08-17 — — JP claimed
EP-1218337-A1 SYNTHESIS OF 3,5,7]-1H-IMIDAZO 1,5-A]IMIDAZOL-2(3H)-ONE COMPOUNDS TORREY PINES INSTITUTE FOR MOLECULAR STUDIES (US) 2002-07-03 — — EP claimed
US-6376548-B1 FUNGICIDES; HERBICIDES; INSECTICIDES ROHM AND HAAS COMPANY 2002-04-23 — — US claimed
US-6359144-B1 BIOSYNTHESIS; SCREENING LION BIOSCIENCE AG (DE) 2002-03-19 — — US claimed
WO-2002008227-A2 BICYCLIC HYDANTOIN DERIVATIVES AND COMBINATORIAL LIBRARIES THEREOF LION BIOSCIENCE AG (DE) 2002-01-31 — — WO claimed
WO-2001019783-A1 SYNTHESIS OF [3,5,7]-1H-IMIDAZO[1,5-A]IMIDAZOL-2(3H)-ONE COMPOUNDS TORREY PINES INSTITUTE FOR MOLECULAR STUDIES (US) 2001-03-22 — — WO claimed
US-5856107-A Combinatorial libraries of imidazol-pyrido-indole and imidazol-pyrido-benzothiophene derivatives, methods of making the libraries and compounds therein TREGA BIOSCIENCES, INC. (US) 1999-01-05 — — US claimed
WO-1998034113-A1 COMBINATORIAL LIBRARIES OF BICYCLIC GUANIDINE DERIVATIVES AND COMPOUNDS THEREIN TREGA BIOSCIENCES, INC. (US) 1998-08-06 — — WO claimed
WO-1998034112-A1 COMBINATORIAL LIBRARIES OF IMIDAZOL-PYRIDO-INDOLES AND IMIDAZOL-PYRIDO-BENZOTHIOPHENE DERIVATIVES TREGA BIOSCIENCES, INC. (US) 1998-08-06 — — WO claimed
EP-0365328-B1 Pyridine derivatives ZENECA LTD (GB) 1996-04-03 — — EP claimed
US-5053415-A Antiischemic, antiinflammatory, antiarthritic agents, cardiovascular disorders IMPERIAL CHEMICAL INDUSTRIES PLC (GB) 1991-10-01 — — US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070100141-A1 SUBSTITUTED PIPERAZINES AND PIPERIDINES AS MODULATORS OF THE NEUROPEPTIDE Y2 RECEPTOR NPY2R, NPY5R, NPY4R NFE2L2 1645/4885TRPA1 839/4885CA1 4074/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback